Research Topics
Genomes and Genes | Giuseppe ToffoliSummaryAffiliation: Centro di Riferimento Oncologico Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapyG Toffoli
Experimental and Clinical Pharmacology, CRO National Cancer Institute, Via Pedemontana Occidentale 12, 33081 Aviano, Italy
J Chemother 16:31-5. 2004..Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the folate cycle, presenting two common polymorphisms (677C>T and 1298 A>C) which have impact on toxicity and efficacy of methotrexate and 5-fluorouracil...- Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patientsGiuseppe Toffoli
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
Int J Cancer 103:294-9. 2003..0004). In conclusion, our data suggest that the TT MTHFR 677 genotype is associated with marked MTX-induced hyperhomocysteinemia and could represent a pharmacogenetic marker for toxicity after chronic treatment with low doses of MTX... - Methylenetetrahydrofolate reductase 677 C-->T polymorphism and risk of proximal colon cancer in north ItalyGiuseppe Toffoli
Experimental and Clinical Pharmacology Unit, Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano PN, Italy
Clin Cancer Res 9:743-8. 2003..The aim of the study was to investigate the role of MTHFR 677 C-->T gene polymorphism in the tumorigenesis of proximal and distal CLC in a monoinstitutional group of patients in North Italy... - Pharmacogenetics of irinotecanG Toffoli
Experimental and Clinical Pharmacology, Unit CRO National Cancer Institute, 33081 Aviano PN, Italy
Curr Med Chem Anticancer Agents 3:225-37. 2003..In this review, we summarise the new developments on the study of the pharmacogenetics of irinotecan, stressing its importance in drug cytotoxic effect... - Pharmacogenomics and stomach cancerGiuseppe Toffoli
Experimental and Clinical Pharmacology, CRO National Cancer Institute, Via Pedemontana Occidentale, 12, 33081 Aviano, Italy
Pharmacogenomics 5:627-41. 2004.... - Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferaseG Toffoli
Unit of Experimental and Clinical Pharmacology, CRO National Cancer Institute, Aviano PN, Italy
Int J Biol Markers 18:218-21. 2003..These results indicate that MTHFR variants are not related to DLBCL development and MGMT hypermethylation... - The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancerGiuseppe Toffoli
Experimental and Clinical Pharmacology Unit, Medical Oncology unit of Centro di Riferimento Oncologico, National Cancer Institute, Via Pedemontana Occidentale, 12, 33081, Aviano, Italy
J Clin Oncol 24:3061-8. 2006..UGT1A1*28 polymorphism has been associated with decreased glucuronidation of SN38, the active metabolite of irinotecan. This could increase toxicity with this agent... - Pharmacokinetic optimisation of treatment with oral etoposideGiuseppe Toffoli
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
Clin Pharmacokinet 43:441-66. 2004..However, they lack precision and accuracy and need to be refined by considering other predictor variables in order to extend their application in current clinical practice... - Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicinG Toffoli
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute 33081 Aviano PN, Italy
J Chemother 16:193-200. 2004..Based on these results we were able to estimate that equiactive plasma drug exposure was reached with an approximately 2.5-fold greater oral dose/m2 of IDA than the corresponding i.v. dose... 
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancerGiuseppe Toffoli
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico National Cancer Institute, Via Pedemontana Occidentale 12, Aviano 33081, Italy
J Clin Oncol 28:866-71. 2010..Prospective genotype-driven studies should test the efficacy of higher irinotecan doses in the FOLFIRI schedule...- Clinical implications of genetic polymorphisms on stomach cancer drug therapyG Toffoli
Experimental and Clinical Pharmacology, CRO-National Cancer Institute, Aviano, Italy
Pharmacogenomics J 7:76-80. 2007 - Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphomaG Toffoli
Experimental and Clinical Pharamcology Unit, National Cancer Institute, Aviano, Italy
Ann Oncol 15:1805-9. 2004..To ascertain the cause of increased toxicity, we investigated the pharmacokinetics of DOX in HIV-patients with NHL treated with CHOP with and without HAART... - Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survivalGiuseppe Toffoli
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico National Cancer Institute, Aviano, Italy
Clin Cancer Res 15:3550-6. 2009..The purpose of this study was to investigate the effect of the TP53 Arg72Pro and the MDM2 SNP309 on the risk of osteosarcoma development and survival... - Pharmacogenetic relevance of MTHFR polymorphismsGiuseppe Toffoli
Experimental and Clinical Pharmacology Unit, CRO National Cancer Institute via Franco Gallini, 2, 33081 Aviano PN, Italy
Pharmacogenomics 9:1195-206. 2008..Further well-designed studies are needed to clarify the role of MTHFR polymorphisms to derive dose adjustment recommendations on the basis of the patient's genotype... - Pharmacology of epidermal growth factor inhibitorsG Toffoli
Clinical and Experimental Pharmacology, Centro di Riferimento Oncologico, Aviano, Pordenone, Italy
Int J Biol Markers 22:S24-39. 2007.... - Pharmacogenetics and stomach cancer: an updateGiuseppe Toffoli
C R O National Cancer Institute, Experimental and Clinical Pharmacology, Via Franco Gallini 2, 33081 Aviano PN, Italy
Pharmacogenomics 8:497-505. 2007..A future challenge is represented by the introduction of targeted therapy in gastric cancer treatment, with the potential emerging tool of pharmacogenetic impact on this field... - Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecanErika Cecchin
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
J Clin Oncol 27:2457-65. 2009..We evaluated the effect of other UGT1A variants and haplotypes involved in 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation on severe toxicity and efficacy of fluorouracil, leucovorin, and irinotecan (FOLFIRI)... - Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patientsErika Cecchin
Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
Clin Cancer Res 11:6901-7. 2005..1%) in the low CES2-expressing group (P = 0.071). CONCLUSION: Our data support a predictive power of CES2 mRNA expression in PBMC for the activation rate of CPT11... - KIR/HLA combination associated with the risk of complications in celiac diseaseLaura Caggiari
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano Italy
Int J Biol Markers 26:221-8. 2011..These results suggest that a KIR haplotype and HLA ligands may be involved in the susceptibility to important clinical CD complications such as tumors or refractoriness as a result of a gluten-free diet... - UGT1A1*28 polymorphism in ovarian cancer patientsErika Cecchin
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute, 33081 Aviano, Italy
Oncol Rep 12:457-62. 2004..In conclusion, the prevalence of UGT1A1*28 found in mucinous OCP could suggest a role in the development of specific histologic sub-groups and could become a marker to be considered when planning ovarian cancer chemotherapy... - C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisationElena De Mattia
Experimental and Clinical Pharmacology Unit, CRO National Cancer Institute, Via Franco Gallini, 2 33081 Aviano PN, Italy
Eur J Cancer 45:1333-51. 2009..The aim of this review is to critically analyse the available data on the importance of MTHFR polymorphisms in modulating the clinical outcome of antifolate and fluoropyrimidine therapies... - Characterization of antibodies directed against the immunoglobulin light kappa chain variable chain region (VK) of hepatitis C virus-related type-II mixed cryoglobulinemia and B-cell proliferationsValli De Re
Experimental and Clinical Pharmacology Unit, Dipartimento di Oncologia Molecolare e Ricerca Traslazionale, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Franco Gallini, 2, 33081 Aviano PN, Italy
Ann N Y Acad Sci 1173:152-60. 2009.... - Pharmacogenetics of stomach cancerGiuseppe Toffoli
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico (CRO, National Cancer Institute, Via Pedemontana Occidentale 12, Aviano, PN
Suppl Tumori 2:S19-22. 2003..In conclusion, the clinical applications of pharmacogenetics could represent a new insight to accurately determine the proper drug and dose to be used in each individual patient... 
Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapyMassimo Libra
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS, Aviano, PN, Italy
BMC Cancer 4:11. 2004..Increased expression of thymidylate synthetase (TS) in CRC metastases has been proposed to be an important mechanism of resistance to fluoropyrimidine-based chemotherapy...- PPAR signaling pathway and cancer-related proteins are involved in celiac disease-associated tissue damageMaria Paola Simula
Experimental and Clinical Pharmacology Unit, CRO Centro diRiferimento Oncologico, IRCCS National Cancer Institute, Aviano PN, Italy
Mol Med 16:199-209. 2010.... - Population pharmacokinetics and pharmacodynamics of oral etoposideG Toffoli
Division of Experimental Oncology 1, Pharmacology Group, Centro di Riferimento Oncologico, National Cancer Center, Aviano, Italy
Br J Clin Pharmacol 52:511-9. 2001..The population PK model based on creatinine clearance is poorly predictive of exposure. Therapeutic drug monitoring would be necessary for dose individualization or to study the relationship between exposure and antitumour effect... - Galectin-10, eosinophils, and celiac diseaseValli De Re
Experimental and Clinical Pharmacology Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
Ann N Y Acad Sci 1173:357-64. 2009..Moreover, our data provide insights into alterations associated with CD tissue damage and pathogenesis... - Differential proteomic analysis of hepatocellular carcinomaGiuseppe Corona
Experimental and Clinical Pharmacology Unit, Department of Molecular Oncology and Translational Medicine, Center for Bimolecular Medicine CBM, National Cancer Institute CRO IRCCS, I 33081 Aviano, Italy
Int J Oncol 36:93-9. 2010..These proteins could represent useful biomarkers to provide new insights into global pathophysiologic changes of HCC and for the development of new pharmacological approaches to HCC therapy... - MTHFR and ALL risk: a challengeGiuseppe Toffoli
Experimental and Clinical Pharmacology Unit, CRO National Cancer Institute, Aviano, Italy
Leuk Lymphoma 47:1203-4. 2006 - High-throughput plasma docetaxel quantification by liquid chromatography-tandem mass spectrometryGiuseppe Corona
Division of Experimental and Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, Aviano PN, Italy
Clin Chim Acta 412:358-64. 2011..A better understanding of docetaxel pharmacokinetic and pharmacodynamic profiles could lead to an improvement in this dose regimen efficacy... - HCV inhibits antigen processing and presentation and induces oxidative stress response in gastric mucosaValli De Re
Experimental and Clinical Pharmacology, CRO Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Aviano, Italy
Proteomics Clin Appl 2:1290-9. 2008..Both these processes facilitate immune escape and cell survival and probably contribute to HCV chronicization... - A novel CDH1 germline missense mutation in a sporadic gastric cancer patient in north-east of ItalyMarica Garziera
Experimental and Clinical Pharmacology Unit, Department of Molecular Oncology and Translational Medicine, DOMERT, IRCCS, National Cancer Institute, Centro di Riferimento Oncologico, Via F Gallini, 2, 33081, Aviano, PN, Italy
Clin Exp Med 13:149-57. 2013..In conclusion, the pathogenicity of this mutation is unlikely; probably we found a new germline CDH1 missense mutation with potential impact, however, of uncertain significance... - Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. Report of three casesMassimo Libra
Division of Medical Ontology, Centro di Riferimento Oncologico, Aviano, Italy
Tumori 89:311-3. 2003..Since patients who relapse after initial treatment with carboplatin often respond to it a second time, it is important to continue this treatment... - Identification of proteins associated to multi-drug resistance in LoVo human colon cancer cellsMichele Visentin
Experimental and Clinical Pharmacology Unit, CRO Centro di Riferimento Oncologico, IRCCS National Cancer Institute, 33081 Aviano PN, Italy
Int J Oncol 34:1281-9. 2009..In conclusion, the proteomic approach indicates that multiple mechanisms are simultaneously involved in MDR. These might be useful in the search for new forms of interventional therapeutic approaches for MDR reversal... - Liquid chromatography tandem mass spectrometry assay for fast and sensitive quantification of estrone-sulfateGiuseppe Corona
National Cancer Institute and Center for Molecular Biomedicine, Aviano, PN, Italy
Clin Chim Acta 411:574-80. 2010..The aim of this study was to develop a rapid and sensitive liquid chromatography-tandem mass spectrometry assay for the determination of estrone-sulfate, suitable for routine clinical investigations... - Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapyPaola Biason
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico National Cancer Institute, Via Franco Gallini, 2, 33081 Aviano, Italy
Pharmacogenomics 13:1609-19. 2012..Original submitted 11 May 2012; Revision submitted 10 August 2012... - 2-D gel electrophoresis: constructing 2D-gel proteome reference mapsMaria Paola Simula
Experimental and Clinical Pharmacology Unit, CRO Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Via F Gallini 2, Aviano PN 33081, Italy
Methods Mol Biol 815:163-73. 2012..The protocol described in this chapter is based on the 2D-DIGE technology and has been applied to obtain the first 2-DE reference map of the human small intestine... - Fast liquid chromatography-tandem mass spectrometry method for routine assessment of irinotecan metabolic phenotypeGiuseppe Corona
Experimental and Clinical Pharmacology Division, National Cancer Institute and Center for Molecular Biomedicine, Aviano, Italy
Ther Drug Monit 32:638-46. 2010..7% to 13.8% and 3.7% to 13.1%, respectively. The method proved to be robust and suitable for therapeutic drug monitoring as well as for pharmacogenetic-pharmacokinetic correlation studies... - Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategiesAlessandro Pavan
Department of Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, Italy
Leuk Lymphoma 49:2048-58. 2008..In this review, the NF-kappaB pathway is suggested as a target for new chemotherapy strategies based on the association of CHOP with molecules more effective than rituximab in this pathway inhibition... - Oral etoposide in elderly patients with advanced non small cell lung cancer: a clinical and pharmacological studyR Sorio
Medical Department, Centro di Riferimento Oncologico, Aviano, Italy
J Chemother 18:188-91. 2006..The easy self-management, favorable toxicity profile and synergy with other compounds makes oral etoposide suitable for further clinical-pharmacological studies in elderly patients... - HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin's lymphoma is related to the type II mixed cryoglobulinemiaV De Re
Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, Italy
Tissue Antigens 75:127-35. 2010..519). Thus, cryoglobulinemia clinical manifestation was found to be correlated with the preferential use of HLA DR-DQ combination in HCV-associated NHL. These data provide new insight into HCV-associated lymphoproliferative pathogenesis... - Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcomaG Corona
Division of Experimental and Clinical Pharmacology, Department of Molecular Oncology and Translational Research, National Cancer Institute, Aviano, Italy
Clin Pharmacol Ther 83:601-6. 2008..0001) in SN38 AUC in the presence of LPV/RTV. The clinical consequences of these substantial pharmacokinetic changes should be investigated... - MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancerValli De Re
Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, Italy
Tumour Biol 31:23-32. 2010..In conclusion, overall findings support the hypothesis that folate plays a role in GC risk. GC-relatives evidence a similar 677TT frequency to that found in the general population... - UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicityP Biason
Clinical and Experimental Pharmacology Division, CRO Centro di Riferimento Oncologico, National Cancer Unstitute, Aviano, Italy
J Chemother 20:158-65. 2008..Further prospective studies are required to reach a personalization of chemotherapy with irinotecan... - Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoringD Crivellari
Division of Medical Oncology C, Centro di Riferimento Oncologico, Aviano, Italy
Ann Oncol 17:807-12. 2006..To determine if protracted low-dose oral idarubicin (IDA), feasible in a previous dose-finding study, would result in similar activity and a better toxicity profile in patients with metastatic breast cancer... - KIR molecules: recent patents of interest for the diagnosis and treatment of several autoimmune diseases, chronic inflammation, and B-cell malignanciesValli De Re
Laboratory of Experimental and Clinical Pharmacology, Department of Molecular Oncology and Translational Medicine DOMERT, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Via F Gallini, 2, 33081 Aviano PN, Italy
Recent Pat DNA Gene Seq 5:169-74. 2011.... - Pharmaco-metabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targetsGiuseppe Corona
Experimental and Clinical Pharmacology Division, IRCCS, National Cancer Institute, Aviano, Pordenone, Italy
J Cell Physiol 227:2827-31. 2012..This review presents the potential role of pharmaco-metabolomics in the future of anticancer pharmacology to achieve customized anticancer treatments and new, targeted therapeutic approaches... - Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agentsMichele Visentin
Experimental and Clinical Pharmacology Unit CRO Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Via Franco Gallini 2, 33081 Aviano PN, Italy
Pharmacol Ther 128:82-90. 2010..Improved molecular characterisation of the EGFR pathway and its complementary pathways in tumor cells is required to better define predictive pharmacokinetic and pharmacodynamic biomarkers for optimum treatment outcome... - A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasmaGiuseppe Corona
Division of Experimental and Clinical Pharmacology, Department ofMolecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, Aviano PN, Italy
J Mass Spectrom 44:920-8. 2009..5-13.2% and - 9.0-5.8% ranges for Exe and DhExe, respectively. The analytical method resulted robust and suitable for pharmacokinetic monitoring of Exe and its main metabolite during adjuvant therapy in patients with breast cancer... - Rapid and sensitive analysis of vincristine in human plasma using on-line extraction combined with liquid chromatography/tandem mass spectrometryGiuseppe Corona
Division of Experimental and Clinical Pharmacology, National Cancer Institute and Center for Molecular Biomedicine, Aviano PN, Italy
Rapid Commun Mass Spectrom 22:519-25. 2008..01% to 6.1%. The proposed assay was found suitable for pharmacokinetics investigations and clinical therapeutic drug monitoring especially in pediatric cancer patients... - New oral drugs in older patients: a review of idarubicin in elderly patientsDiana Crivellari
Medical Oncology Department, Centro di Riferimento Oncologico, Via Pedemontana Occ, 12, 33081 Aviano, PN, Italy
Crit Rev Oncol Hematol 49:153-63. 2004..The pharmacokinetics, activity, adverse effects and new modalities of oral administration are reviewed... - Sarcomas and pharmacogeneticsPaola Biason
CRO, National Cancer Institute, Experimental and Clinical Pharmacology, Via Pedemontana Occidentale, 12 33081 Aviano, PN, Italy
Pharmacogenomics 6:585-601. 2005..For STS and sarcoma of the bone, the genetic markers, which could be unambiguously predictive of the phenotypic profile of patients, are as yet undetermined... - High throughput screening of genetic polymorphisms by matrix-assisted laser desorption ionization time-of-flight mass spectrometryGiuseppe Corona
Experimental and Clinical Pharmacology Unit, National Cancer Institute, Via Pedemontana Occ. 12, 33081 Aviano (PN) Italy
Comb Chem High Throughput Screen 7:707-25. 2004..In this review, we analyze and discuss in depth the advantages and the limitations of the more recent developments in MALDI-TOF MS analysis for large-scale genomic studies applications... - Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unitM De Cicco
Department of Anesthesiology, Centro di Riferimento Oncologico, Istituto Nazionale Tumori Centroeuropeo, Aviano, Italy
Crit Care Med 27:332-9. 1999..Our study aimed at evaluating the pharmacokinetic, cardiovascular, and metabolic effects of high-dose verapamil continuous intravenous infusion in cancer patients... - miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?Eva Dreussi
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico National Cancer Institute, Via Franco Gallini, 2, 33081 Aviano, Italy
Pharmacogenomics 13:1635-50. 2012..This review summarizes the most recent and promising results in the field and gives an overview of the future perspective of personalized cancer therapy... - Two-dimensional gel proteome reference map of human small intestineMaria Paola Simula
Experimental and Clinical Pharmacology, CRO Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Via F, Gallini 2, 33081 Aviano, PN, Italy
Proteome Sci 7:10. 2009..Spots identifications, reported in a database, will be helpful to identify the variability in protein expression levels, in isoforms expression, or in post-translational modifications associated to pathology or to a therapy... - Pharmacokinetics of doxorubicin co-administered with high-dose verapamilM Gigante
Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Italy
Br J Cancer 71:134-6. 1995..No significant difference was found between the kinetic parameters estimated for DOX at different levels of VER and those reported for doxorubicin as single agent. It can be concluded that VER does not appear to modify DOX kinetics... - Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell linesG Toffoli
Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Italy
Br J Cancer 63:51-6. 1991.... - Dissecting Pin1 and phospho-pRb regulationFlavio Rizzolio
Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania 19122, USA
J Cell Physiol 228:73-7. 2013.... - Recent patents relating to HCV molecules like putative targets for therapeutic interventionValli De Re
Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, Pordenone, Italy
Recent Pat DNA Gene Seq 1:186-94. 2007.... - Lack of association of CYP1 B1*3 polymorphism and ovarian cancer in a Caucasian populationE Cecchin
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico National Cancer Institute, Aviano, Italy
Int J Biol Markers 19:160-3. 2004..No significant difference between cases and controls was found. These results do not support a favoring role of CYP1B1*3 in ovarian cancer development in our population... - Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposideG Toffoli
Department of Experimental Oncology, Centro di Riferimento Oncologico, Aviano PN, Italy
Br J Cancer 75:715-21. 1997..CSA affected both the pharmacokinetics and pharmacodynamics of VM26 in the patients, principally by increasing the plasma concentrations of the antineoplastic drug and VM26 haemopoietic toxicity... - Frequent occurrence of Ha-rasl allelic deletion in human ovarian adenocarcinomasA Viel
Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Pordenone, Italy
Tumori 77:16-20. 1991..These findings may suggest that a putative tumor suppressor gene closely linked to Ha-rasl in 11p15.5 is involved in ovarian cancerogenesis... - Changes in chemosensitivity of K 562 leukemia cells after induction of erythroid differentiation by heminG Toffoli
Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Pordenone, Italia
Tumori 74:11-7. 1988..The results obtained by chemosensitivity tests showed a generalized decrease in chemosensitivity of the K 562 cells to all the drugs tested as a consequence of the hemin-induced differentiation... - P-glycoprotein but not topoisomerase II and glutathione-S-transferase-pi accounts for enhanced intracellular drug-resistance in LoVo MDR human cell linesM Boiocchi
Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Italy
Tumori 78:159-66. 1992.... - Prevalence of methylenetetrahydrofolate reductase polymorphisms in young patients with inflammatory bowel diseaseGabriele Stocco
Department of Biomedical Sciences, University of Trieste, Trieste, Italy
Dig Dis Sci 51:474-9. 2006..The incidence of mutations in the MTHFR gene was not different between patients with IBD and control subjects; the mutated genotype was not associated with an increased risk of toxicity during thiopurine treatment... - Tailored therapy of colorectal cancer: results, challenges and future directionsGiampietro Gasparini
Division of Medical Oncology, S Filippo Neri Hospital, Universita Cattolica del Sacro Cuore, Rome, Italy
Cancer J 11:175-88. 2005..Further efforts are needed to improve the reliability of genomic and proteomic technologies, in particular regarding their standardization and widespread availability. These unsolved issues make tailored therapy an open challenge... - IdarubicinDiana Crivellari
Centro di Riferimento Oncologico, Aviano (PN
Tumori 88:S73-4. 2002 - Is tailored therapy feasible in oncology?Giampietro Gasparini
Division of Medical Oncology, Azienda Complesso Ospedaliero di Rilevanza Nazionale S Filippo Neri Hospital, via G Martinotti 20, 00135 Rome, Italy
Crit Rev Oncol Hematol 57:79-101. 2006..In addition, further efforts are needed to improve the reliability of genomic and proteomic technologies. These unsolved issues presently make tailored therapy an open challenge... - Carboplatin in elderly patientsRoberto Sorio
National Cancer Institute, Aviano (PN
Tumori 88:S35-6. 2002 - Potential hazard of pharmacokinetic interactions between lopinavir-ritonavir protease inhibitors and irinotecanGiuseppe Corona
AIDS 19:2043-4. 2005 - Mixed cryoglobulinemia syndrome as an additional autoimmune disorder associated with risk for lymphoma developmentValli De Re
Blood 111:5760. 2008 - Carboplatin and topotecan combination and myelosuppressionGiuseppe Toffoli
J Clin Oncol 20:3558. 2002 - Radiosensitivity in multidrug-resistant and cisplatin-resistant human carcinoma cell linesMarco Gigante
School of Radiotherapy, University of Padua, Padua, Italy
Am J Clin Oncol 26:e73-9. 2003..The total glutathione content (GSH) of C13 cells was 1.5-fold higher than that of 2008 cells. BSO treatment caused a partial depletion of GSH in 2008 and C13 cells, but their radiosensitivity did not change accordingly...